RGEN — REPLIGEN CORP
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 730272 ·
Last close
$163.84
Market Cap
$9.25B
52W High
$198.87
52W Low
$100.99
ADV30
1,174,421
Next earnings
2026-11-03
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 204,128,000 | 110,037,000 | 19,002,000 | 5,008,000 | 2,950,180,000 | 606,783,000 | 838,148,000 |
| Mar 2026 | — | — | — | — | — | — | — |
| Dec 2025 | 197,913,000 | 103,831,000 | 16,348,000 | 13,287,000 | 2,949,699,000 | 566,021,000 | 843,570,000 |
| Sep 2025 | 188,805,000 | 100,515,000 | 12,677,000 | 14,911,000 | 2,923,711,000 | 748,747,000 | 840,624,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$134,864,000
Investing CF
$-222,604,000
Financing CF
$-11,787,000
CapEx
$-24,711,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.73
As of
2026-08-02
Balance + Analyst (yfinance extras)
Retained Earnings
$469,589,000
Inventory
$186,604,000
Receivables
$157,710,000
ST Investments
$203,666,000
EBIT TTM
$74,300,000
Pretax Income TTM
$52,150,000
Interest Exp TTM
$22,150,000
Analysts
20
Yahoo Snapshot (yfinance, live)
Total Revenue
$785,100,992
EBITDA
$144,100,992
Free Cash Flow
$113,421,752
Enterprise Value
$9,202,529,280
Total Cash
$810,449,024
Total Debt
$690,942,016
Shares Out
56,435,621
Trailing EPS
$0.73
Book Value
$37.43
ROE
2.0%
ROA
1.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 738,256,000 | 41,560,000 | 48,894,000 | 2,949,699,000 | 843,570,000 | 2,106,129,000 | 117,417,000 |
| Dec 2024 | 634,439,000 | -31,923,000 | -25,514,000 | 2,829,666,000 | 856,948,000 | 1,972,718,000 | 175,394,000 |
| Dec 2023 | 632,362,000 | 17,134,000 | 35,596,000 | 2,831,185,000 | 866,340,000 | 1,964,845,000 | 113,918,000 |
| Dec 2022 | 801,536,000 | 195,941,000 | 185,959,000 | 2,531,600,000 | 620,900,000 | 1,910,700,000 | 172,083,000 |
TTM Snapshot
Revenues TTM
$763,339,000
NetIncome TTM
$51,397,000
OpCashFlow TTM
—
Assets (Latest)
$2,930,772,000
Forward EPS
$2.65
Max Pain — expiry 2026-10-16
max pain strike: $185.00 · spot: $163.84 · call oi: 2,773 · put oi: 2,399
Expected Move to 2026-10-16:
±$12.12
(7.40%) —
implied range
$151.72 –
$175.96
· ATM straddle on $165.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| QGEN | QIAGEN N.V. | $9.20B | $44.53 | — |
| KYMR | Kymera Therapeutics, Inc. | $8.99B | $109.30 | — |
| PCVX | Vaxcyte, Inc. | $9.67B | $65.01 | — |
| KRYS | Krystal Biotech, Inc. | $9.69B | $327.30 | — |
| TWST | Twist Bioscience Corp | $10.08B | $152.05 | — |
News headlines (Yahoo Finance, 1h cache)
Repligen Completes Acquisition of BioLife Solutions
2026-10-06 13:05 · Yahoo
3 Unpopular Stocks Walking a Fine Line
2026-09-23 09:17 · Yahoo
Freshworks Set to Join S&P SmallCap 600
2026-10-05 22:29 · Yahoo
Freshworks stock climbs on S&P SmallCap 600 inclusion
2026-10-05 21:54 · Yahoo
BioLife Solutions Shareholders Approve Repligen Merger Agreement
2026-10-05 17:02 · Yahoo
Why Are Freshworks (FRSH) Shares Soaring Today
2026-10-06 20:48 · Yahoo
3 Healthcare Stocks That Concern Us
2026-10-02 11:02 · Yahoo
Why Did KOD, RGEN, BIIB Stocks Rise To 52-Week Highs?
2026-09-29 04:23 · Yahoo
Merck's Remigromig Meets Main Goal in Diabetic Macular Edema Study
2026-09-25 14:19 · Yahoo
AMGN's Dazodalibep Meets Goal in Systemic Sjogren's Disease Study
2026-09-23 14:38 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.